Peter is a chemist, with a Master’s degree in analytical chemistry, who has over 40 years’ experience of pharmaceutical manufacture, control and quality management. In 2016 he was awarded an honorary Doctor of Science degree by Kingston University, London, for services to pharmaceutical quality management. He held numerous positions at Eli Lilly over a 30 year career, culminating in the role of Senior Quality Consultant in Eli Lilly’s Global Quality Systems division, before he joined NSF in 2005. He has broad experience, particularly with quality control laboratories and the manufacture of solid dosage forms and active pharmaceutical ingredients. Peter has extensive experience of pharmaceutical law and in defining quality systems at a global level. He is a former member of the European Federation of Pharmaceutical Industry Association’s (EFPIA) Manufacturing and GMP ad hoc group and was EFPIA topic leader on the ICH Expert Working Group which prepared the Q9 guideline on Quality Risk Management. He was given the “Leveraging Collaboration Award” by the US FDA for his contribution to the on-line ICH Q9 briefing pack. Since the vote to leave the EU in June 2016, he has been providing regular commentary on the potential impacts of Brexit on the legal position for the supply of medicines in the UK and the EU. Peter is a recognised expert on the role of the Qualified Person (QP), having been eligible to act as a QP since 1985. He is a past chairman of the Royal Society of Chemistry’s Qualified Person Assessor panel. He is a Fellow of the Royal Society of Chemistry and of the UK Chartered Quality Institute (CQI) and is a former chairman of the CQI’s Pharmaceutical Quality Group. He is an Honorary Lecturer on pharmaceutical quality management and GMP at the University of Strathclyde.